Logo image of ABIO.PA

Albioma SA (ABIO.PA) Stock Fundamental Analysis

Europe - EPA:ABIO - FR0000060402 - Common Stock

47.14 EUR
+0.04 (+0.08%)
Last: 9/13/2022, 7:00:00 PM
Fundamental Rating

2

ABIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 21 industry peers in the Independent Power and Renewable Electricity Producers industry. ABIO has a bad profitability rating. Also its financial health evaluation is rather negative. ABIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ABIO was profitable.
ABIO.PA Yearly Net Income VS EBIT VS OCF VS FCFABIO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M 100M 150M

1.2 Ratios

Industry RankSector Rank
ROA 2.71%
ROE 9.81%
ROIC 5.3%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABIO.PA Yearly ROA, ROE, ROICABIO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2 4 6 8 10

1.3 Margins

Industry RankSector Rank
OM 19.98%
PM (TTM) 8.98%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABIO.PA Yearly Profit, Operating, Gross MarginsABIO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ABIO is still creating some value.
ABIO has more shares outstanding than it did 1 year ago.
ABIO has a worse debt/assets ratio than last year.
ABIO.PA Yearly Shares OutstandingABIO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
ABIO.PA Yearly Total Debt VS Total AssetsABIO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 1.46, we must say that ABIO is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 1.68 is on the high side and indicates that ABIO has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.68
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACC1.11
WACC4.79%
ABIO.PA Yearly LT Debt VS Equity VS FCFABIO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M

2.3 Liquidity

ABIO has a Current Ratio of 1.05. This is a normal value and indicates that ABIO is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 0.75 indicates that ABIO may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.75
ABIO.PA Yearly Current Assets VS Current LiabilitesABIO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

ABIO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.36%.
Measured over the past years, ABIO shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.59% on average per year.
The Revenue has grown by 21.04% in the past year. This is a very strong growth!
The Revenue has been growing by 9.28% on average over the past years. This is quite good.
EPS 1Y (TTM)4.36%
EPS 3Y8.34%
EPS 5Y10.59%
EPS Q2Q%-11.09%
Revenue 1Y (TTM)21.04%
Revenue growth 3Y10.21%
Revenue growth 5Y9.28%
Sales Q2Q%22.65%

3.2 Future

Based on estimates for the next years, ABIO will show a small growth in Earnings Per Share. The EPS will grow by 7.39% on average per year.
ABIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.22% yearly.
EPS Next Y4%
EPS Next 2Y10.38%
EPS Next 3Y7.07%
EPS Next 5Y7.39%
Revenue Next Year8.28%
Revenue Next 2Y6.4%
Revenue Next 3Y6.91%
Revenue Next 5Y6.22%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ABIO.PA Yearly Revenue VS EstimatesABIO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
ABIO.PA Yearly EPS VS EstimatesABIO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 26.94, ABIO can be considered very expensive at the moment.
Compared to an average S&P500 Price/Earnings ratio of 27.38, ABIO is valued at the same level.
With a Price/Forward Earnings ratio of 21.36, ABIO is valued on the expensive side.
The average S&P500 Price/Forward Earnings ratio is at 22.86. ABIO is around the same levels.
Industry RankSector Rank
PE 26.94
Fwd PE 21.36
ABIO.PA Price Earnings VS Forward Price EarningsABIO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.89
ABIO.PA Per share dataABIO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)6.74
PEG (5Y)2.54
EPS Next 2Y10.38%
EPS Next 3Y7.07%

More info and screens

2

5. Dividend

5.1 Amount

ABIO has a Yearly Dividend Yield of 1.78%.
ABIO's Dividend Yield is slightly below the S&P500 average, which is at 2.38.
Industry RankSector Rank
Dividend Yield 1.78%

5.2 History

The dividend of ABIO is nicely growing with an annual growth rate of 8.92%!
Dividend Growth(5Y)8.92%
Div Incr YearsN/A
Div Non Decr YearsN/A
ABIO.PA Yearly Dividends per shareABIO.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 0.2 0.4 0.6 0.8

5.3 Sustainability

The dividend of ABIO is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DPN/A
EPS Next 2Y10.38%
EPS Next 3Y7.07%
ABIO.PA Yearly Income VS Free CF VS DividendABIO.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

More info and screens

Albioma SA

EPA:ABIO (9/13/2022, 7:00:00 PM)

47.14

+0.04 (+0.08%)

Chartmill FA Rating
GICS SectorUtilities
GICS IndustryGroupUtilities
GICS IndustryIndependent Power and Renewable Electricity Producers
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.52B
Analysts80
Price Target52.53 (11.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.78%
Yearly Dividend0.84
Dividend Growth(5Y)8.92%
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 26.94
Fwd PE 21.36
P/S 2.4
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB N/A
EV/EBITDA 11.89
EPS(TTM)1.75
EY3.71%
EPS(NY)2.21
Fwd EY4.68%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS19.64
BVpS17.99
TBVpSN/A
PEG (NY)6.74
PEG (5Y)2.54
Profitability
Industry RankSector Rank
ROA 2.71%
ROE 9.81%
ROCE N/A
ROIC 5.3%
ROICexc N/A
ROICexgc 5.8%
OM 19.98%
PM (TTM) 8.98%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 1.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 0.75
Altman-Z 1.46
F-Score6
WACC4.79%
ROIC/WACC1.11
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.36%
EPS 3Y8.34%
EPS 5Y10.59%
EPS Q2Q%-11.09%
EPS Next Y4%
EPS Next 2Y10.38%
EPS Next 3Y7.07%
EPS Next 5Y7.39%
Revenue 1Y (TTM)21.04%
Revenue growth 3Y10.21%
Revenue growth 5Y9.28%
Sales Q2Q%22.65%
Revenue Next Year8.28%
Revenue Next 2Y6.4%
Revenue Next 3Y6.91%
Revenue Next 5Y6.22%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A